Aquestive Therapeutics Licensing Deal with Eton Pharmaceuticals, Inc. Worth $57.5M
Aquestive Therapeutics granted Eton Pharmaceuticals exclusive U.S. rights to commercialize LIBERVANT (diazepam) buccal film for the treatment of seizure clusters in epilepsy patients. Aquestive received a $10 million upfront fee and is eligible for up to $47.5 million in regulatory and commercial milestones, plus mid-teens royalties on net sales. Aquestive will remain the exclusive manufacturer and supplier of the product for an initial 20-year term.
- Value
- $57.5M
- Counterparty
- Eton Pharmaceuticals, Inc.
- Term
- 20 years